Abstract
The objective of this report is to discuss the potential for normal hormone regulation and application of chronic phosphodiesterase type 5 inhibition for the management of recurrent ischemic priapism. A 64-year-old man presented with refractory priapism treated with antiandrogen therapy. He was transitioned to and well controlled on a regimen of daily phosphodiesterase type 5 inhibitor and every other week antiandrogen therapy. Our treatment of recurrent priapism implicates androgens and both biochemical and neurovascular control mechanisms in the penis.
MeSH terms
-
Androgen Antagonists / adverse effects
-
Anilides / adverse effects
-
Humans
-
Male
-
Nitriles / adverse effects
-
Penis / blood supply
-
Phosphodiesterase 5 Inhibitors / administration & dosage
-
Phosphodiesterase 5 Inhibitors / therapeutic use*
-
Piperazines / administration & dosage
-
Piperazines / therapeutic use*
-
Priapism / drug therapy*
-
Purines / administration & dosage
-
Purines / therapeutic use
-
Recurrence
-
Sildenafil Citrate
-
Sulfones / administration & dosage
-
Sulfones / therapeutic use*
-
Tosyl Compounds / adverse effects
Substances
-
Androgen Antagonists
-
Anilides
-
Nitriles
-
Phosphodiesterase 5 Inhibitors
-
Piperazines
-
Purines
-
Sulfones
-
Tosyl Compounds
-
bicalutamide
-
Sildenafil Citrate